We aimed to compare the prevalence of molecular groups at poor and intermediate prognosis (p53-abn and MMR-d groups) between endometrial cancer patients with and without coexistent adenomyosis through a multicentric, observational, retrospective, cohort study. Here, TP53 is linked to endometrial cancer.